title: Intracoronary administration of cardiac stem cells in mice: a new, improved technique for cell therapy in murine models.
abstract: A model of intracoronary stem cell delivery that enables transgenesis/gene targeting would be a powerful tool but is still lacking. To address this gap, we compared intracoronary and intramyocardial delivery of lin(-)/c-kit(+)/GFP(+) cardiac stem cells (CSCs) in a murine model of reperfused myocardial infarction (MI). Lin(-)/c-kit(+)/GFP(+) CSCs were successfully expanded from GFP transgenic hearts and cultured with no detectable phenotypic change for up to ten passages. Intracoronary delivery of CSCs 2 days post-MI resulted in significant alleviation of adverse LV remodeling and dysfunction, which was at least equivalent, if not superior, to that achieved with intramyocardial delivery. Compared with intramyocardial injection, intracoronary infusion was associated with a more homogeneous distribution of CSCs in the infarcted region and a greater increase in viable tissue in this region, suggesting greater formation of new cardiomyocytes. Intracoronary CSC delivery resulted in improved function in the infarcted region, as well as in improved global LV systolic and diastolic function, and in decreased LV dilation and LV expansion index; the magnitude of these effects was similar to that observed after intramyocardial injection. We conclude that, in the murine model of reperfused MI, intracoronary CSC infusion is at least as effective as intramyocardial injection in limiting LV remodeling and improving both regional and global LV function. The intracoronary route appears to be superior in terms of uniformity of cell distribution, myocyte regeneration, and amount of viable tissue in the risk region. To our knowledge, this is the first study to report that intracoronary infusion of stem cells in mice is feasible and effective.
authors.affiliation: Division of Cardiovascular Medicine, University of Louisville, 550 S. Jackson Street, Louisville, KY 40292, USA.
authors.forename: Qianhong
authors.initials: Q
authors.lastname: Li
authors.forename: Yiru
authors.initials: Y
authors.lastname: Guo
authors.forename: Qinghui
authors.initials: Q
authors.lastname: Ou
authors.forename: Ning
authors.initials: N
authors.lastname: Chen
authors.forename: Wen-Jian
authors.initials: WJ
authors.lastname: Wu
authors.forename: Fangping
authors.initials: F
authors.lastname: Yuan
authors.forename: Erin
authors.initials: E
authors.lastname: O'Brien
authors.forename: Tao
authors.initials: T
authors.lastname: Wang
authors.forename: Li
authors.initials: L
authors.lastname: Luo
authors.forename: Gregory N
authors.initials: GN
authors.lastname: Hunt
authors.forename: Xiaoping
authors.initials: X
authors.lastname: Zhu
authors.forename: Roberto
authors.initials: R
authors.lastname: Bolli
mesh_terms: D000818:Animals; D002465:Cell Movement / Q000502:physiology; D064987:Cell- and Tissue-Based Therapy / Q000379:methods*; D002478:Cells, Cultured; D003331:Coronary Vessels; D005260:Female; D049452:Green Fluorescent Proteins / Q000378:metabolism; D007269:Injections, Intra-Arterial; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D023421:Models, Animal; D009203:Myocardial Infarction / Q000473:pathology / Q000628:therapy*; D009206:Myocardium / Q000166:cytology* / Q000378:metabolism; D019009:Proto-Oncogene Proteins c-kit / Q000378:metabolism; D012038:Regeneration / Q000502:physiology; D013234:Stem Cells / Q000166:cytology* / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D049452:Green Fluorescent Proteins; D019009:Proto-Oncogene Proteins c-kit